Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Urothelial Cancer × Everolimus × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 44 Carcinoma, Renal Cell 25 Neoplasm Metastasis 15 Neoplasms 13 Kidney Neoplasms 11 Neuroendocrine Tumors 10 Carcinoma, Neuroendocrine 9 Prostatic Neoplasms 7 Thyroid Neoplasms 6 Sarcoma 6 Meningioma 6 Melanoma 6 Lymphoma 6 Tuberous Sclerosis 5 Recurrence 5 Lymphoma, Mantle-Cell 5 Head and Neck Neoplasms 5 Endometrial Neoplasms 5 Carcinoma 5 Triple Negative Breast Neoplasms 4 Pancreatic Neoplasms 4 Ovarian Neoplasms 4 Lymphoma, Large B-Cell, Diffuse 4 Glioma 4 Colorectal Neoplasms 4 Carcinoma, Hepatocellular 4 Astrocytoma 4 Urinary Bladder Neoplasms 3 Stomach Neoplasms 3 Neurofibromatosis 2 3

Interventions

erdafitinib 1 atezolizumab 1 Tiragolumab 1 Sunitinib 1 Paclitaxel 1 Midazolam 1 Metformin 1 Gemcitabine 1 Everolimus 1 Cisplatin 1 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01801137 2016-06-21

AFINIVEST

Hopital Foch

Phase 2 Completed

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡